Yusuke Satake
Principal @ Keio Innovation Initiative
Tokyo, Japan
Yusuke Satake is a Series A investor at Keio Innovation Initiative in Tokyo focused on Medical and Health Care. Yusuke Satake is the principal at Keio Innovation Initiative.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Yusuke Satake invests in
Stages Yusuke Satake invests in
Countries Yusuke Satake invests in
Investment Focus
Industry
- Medical 2 (50%)
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Pharmaceutical 2 (50%)
- Health Diagnostics 2 (50%)
Stage
- Series A 3 (75%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Fermelanta
|
Fermelanta produces rare plant-based ingredients through microbial fermentation. It engineers a cell to build a biosynthetic pathway of target molecules with gene transfer and disruption. | $13.6M / Series A / Aug 29, 2025 | |
Linqmed
|
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $15.9M / Series B / Apr 09, 2025 | |
Purmx
|
PURMX is a pharmaceutical company that develops RNA nucleic acid medicine for therapeutic effects on intractable diseases. | Series A / May 07, 2024 | |
Hedgehog MedTech
|
Hedgehog Medtech is a medical firm focused on digital therapeutics (DTx). DTx is a pharmaceutically approved programmable medical device that assists patients' medical operations via smartphone apps. | $3.4M / Series A / Dec 01, 2023 |
Co-Investors
About Keio Innovation Initiative
Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.
Keio Innovation Initiative Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Kotaro Yamagishi
Founder & CEO
|
|||
Shuichi Kinoshita
corporate officer
|
|||
|
Yusuke Satake
Principal
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Yusuke Satake invest in?
Yusuke Satake invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Yusuke Satake last invest?
The most recent investment recorded for Yusuke Satake closed in Aug 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
